Vis enkel innførsel

dc.contributor.authorSyversen, Silje Watterdal
dc.contributor.authorJyssum, Ingrid
dc.contributor.authorTveter, Anne Therese
dc.contributor.authorSexton, Joseph
dc.contributor.authorChristensen, Ingrid Egeland
dc.contributor.authorTran, Trung
dc.contributor.authorHammersbøen, Kristin Reine
dc.contributor.authorMjaaland, Siri
dc.contributor.authorWarren, David
dc.contributor.authorKvien, Tore Kristian
dc.contributor.authorChopra, Adity
dc.contributor.authorKro, Grete Anette Birkeland
dc.contributor.authorJahnsen, Jørgen
dc.contributor.authorMunthe, Ludvig Andre
dc.contributor.authorHaavardsholm, Espen A.
dc.contributor.authorGrødeland, Gunnveig
dc.contributor.authorVaage, John T.
dc.contributor.authorProvan, Sella Aarrestad
dc.contributor.authorJørgensen, Kristin Kaasen
dc.contributor.authorGoll, Guro Løvik
dc.date.accessioned2023-01-25T13:05:15Z
dc.date.available2023-01-25T13:05:15Z
dc.date.created2022-11-30T13:18:50Z
dc.date.issued2022
dc.identifier.citationRMD Open. 2022, 8 (2), .
dc.identifier.issn2056-5933
dc.identifier.urihttps://hdl.handle.net/11250/3046322
dc.language.isoeng
dc.titleImmunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
dc.title.alternativeImmunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersion
dc.source.pagenumber9
dc.source.volume8
dc.source.journalRMD Open
dc.source.issue2
dc.identifier.doi10.1136/rmdopen-2022-002417
dc.identifier.cristin2085677
dc.relation.projectNorges forskningsråd: 328657
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel